IBA and Framatome join forces to industrialize Astatine-211 production for cancer therapies
Louvain-la-Neuve, Belgium, and Paris, France, 16 October 2026, 8:00 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and radiopharmaceutical production solutions, and Framatome, an international leader in nuclear energy committed, among other activities, to the industrial development of products and services for human health through its Framatome Healthcare brand, today announce the establishment of a joint venture (JV) named Ekalia, with its dedicated logo:
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.